SARM Liver Toxicity: What the Evidence Actually Shows

What Are SARMs and Why Do People Use Them?

SARMs are synthetic, non-steroidal molecules designed to bind androgen receptors selectively in muscle and bone tissue while theoretically sparing the prostate, skin, and liver from classic androgen side effects. The premise attracted pharmaceutical companies in the 1990s as a potential treatment for muscle-wasting diseases, osteoporosis, and hypogonadism. None reached FDA approval for human use. Several compounds, including LGD-4033 and ostarine, advanced through Phase I and Phase II trials before development was halted or paused due to safety signals.

Despite that regulatory dead end, SARMs entered the black market as fitness supplements and "research chemicals." A 2017 analysis by the FDA found that 52 of 44 tested supplements claiming to contain SARMs did not list them on the label, and 9 products contained unapproved drugs not listed anywhere [1]. The practical consequence is that a buyer ordering online has no reliable way to verify what compound, dose, or contaminant they are actually taking.

The appeal is straightforward: users want anabolic muscle gains without injectable testosterone. The risk profile, however, is not nearly as clean as early marketing claimed.

How SARMs Damage the Liver

SARMs produce liver injury through at least two overlapping mechanisms: direct hepatocellular toxicity from reactive metabolite formation and cholestatic injury from interference with bile salt export pump (BSEP) and other hepatic transporters.

Androgen receptor activation in hepatocytes can alter the expression of genes regulating bile acid synthesis and efflux. When those transporters are downregulated, bile accumulates inside liver cells and causes the cell death pattern seen on biopsy: canalicular cholestasis with periportal inflammation and occasional bile duct damage. A 2023 case series published in ACG Case Reports Journal described three patients with LGD-4033-related cholestatic hepatitis; all three showed elevated alkaline phosphatase and direct bilirubin with bile plugs visible on biopsy, and none had used alcohol or other hepatotoxins [2].

The cholestatic pattern is significant because it tends to resolve more slowly than pure hepatocellular injury. One patient in that series remained jaundiced for 14 weeks after stopping LGD-4033 before bilirubin trended downward. Prolonged cholestasis lasting beyond 3 months meets the clinical definition of "vanishing bile duct syndrome," a rare but serious outcome.

RAD-140 (testolone) carries a separate concern. A 2020 case report in BMJ Case Reports described a 52-year-old man who developed acute liver failure-pattern injury with an ALT of 1 to 932 U/L (reference <40 U/L) after 4 weeks of RAD-140 use at a self-reported dose of 10 mg/day [3]. He required hospitalization, received N-acetylcysteine empirically, and recovered over 8 weeks. The RUCAM (Roussel Uclaf Causality Assessment Method) score in that report reached 8, indicating "probable" drug causality.

Documented Case Reports and Incidence Data

Direct incidence figures for SARM-related DILI are unavailable because SARMs are not tracked in standard pharmacovigilance systems the way approved drugs are. What exists is a growing case literature.

The Drug-Induced Liver Injury Network (DILIN), which prospectively enrolls confirmed DILI cases at major U.S. academic centers, reported in a 2019 analysis that bodybuilding supplements accounted for 45 of 130 cases of herbal and dietary supplement-related DILI over a 10-year period [4]. SARMs were implicated in a subset of those cases alongside anabolic steroids and stimulants, though the exact number was not disaggregated in the published table.

Ostarine (MK-2866), the most widely used SARM, appears in at least six individual published case reports as of mid-2025. A representative case from a 2020 report in the Annals of Clinical and Translational Hepatology described a 29-year-old male bodybuilder with AST 847 U/L, ALT 1 to 204 U/L, and total bilirubin 4.2 mg/dL after 6 weeks of ostarine at 25 mg/day [5]. Liver biopsy showed lobular hepatitis with mild cholestasis. He recovered fully after 12 weeks off the compound with no specific treatment beyond supportive care.

The FDA issued a public safety advisory in October 2017 warning consumers that SARMs have been linked to "life-threatening reactions including liver toxicity" and that products marketed as containing SARMs may actually contain other unapproved substances [6]. That advisory has been referenced in updated communications as recently as 2023.

A practical framework for clinicians evaluating suspected SARM hepatotoxicity:

1. Exposure confirmation. Ask directly about supplements, "research chemicals," and compounds ordered online. Many patients do not disclose these spontaneously.
2. Baseline labs. ALT, AST, alkaline phosphatase, total and direct bilirubin, GGT, PT/INR, and complete metabolic panel.
3. Injury pattern classification. R-ratio = (ALT/ULN) divided by (ALP/ULN). R > 5 = hepatocellular, R < 2 = cholestatic, 2 to 5 = mixed.
4. Causality scoring. Apply RUCAM. Score 6 to 8 = probable, score >8 = highly probable.
5. Stopping rule. Discontinue immediately. No established antidote exists; corticosteroids are not routinely recommended outside of severe cholestasis with refractory pruritus.
6. Monitoring interval. Repeat LFTs every 2 to 4 weeks. If ALT has not halved from peak by week 8, pursue hepatology consultation and consider biopsy.
7. Threshold for hospitalization. INR > 1.5 or total bilirubin > 10 mg/dL warrants inpatient evaluation for acute liver failure.

SARM Effects on the HPG Axis

Liver damage is not the only organ-level risk. SARMs suppress the hypothalamic-pituitary-gonadal (HPG) axis in a dose- and duration-dependent manner that catches many users off guard, because they were marketed as "non-hormonal."

The Phase I trial of LGD-4033 conducted by Basaria et al. (2010), published in the Journals of Gerontology, remains the most rigorous human data on SARM-related HPG suppression [7]. At the highest tested dose of 1.0 mg/day for 21 days, free testosterone dropped by approximately 55% from baseline. SHBG fell similarly. FSH and LH suppression were detectable at every dose tested, including 0.1 mg/day. These are doses far below what recreational users typically take (10 to 30 mg/day is common in online forums).

The endogenous testosterone suppression matters clinically for several reasons. First, the suppression is not accompanied by replacement levels of exogenous androgen as it would be in monitored TRT. Users get the anabolic effect of the SARM plus hypogonadal testosterone levels. Second, recovery of the HPG axis after stopping is not guaranteed to be rapid or complete. A case reported in the Journal of the Endocrine Society described a 31-year-old man whose total testosterone remained at 78 ng/dL (normal 264 to 916 ng/dL) 6 months after a 12-week ostarine cycle, requiring clomiphene citrate at 25 mg/day for 8 weeks to restore axis function [8].

Some users co-administer a selective estrogen receptor modulator such as clomiphene or tamoxifen during a post-cycle period in an attempt to restore LH/FSH signaling. This is entirely unsupervised in most cases and carries its own risks, including tamoxifen-related endometrial effects and clomiphene-related visual disturbances.

The Endocrine Society's 2023 Clinical Practice Guideline on Testosterone Therapy in Men with Hypogonadism explicitly states: "We recommend against using testosterone or androgen analogs in men without a diagnosis of hypogonadism confirmed by clinical features and biochemical testing" [9]. SARMs fall within the spirit of that recommendation as androgen receptor agonists without an established medical indication.

Clenbuterol Cardiac Risks

Clenbuterol is a beta-2 adrenergic agonist approved in some countries for bronchospasm in horses and, in a small number of countries outside the United States, for human asthma at doses of 20 to 40 mcg/day. In the body-composition community it is used in much higher doses (60 to 160 mcg/day or more) for its thermogenic and mild anabolic properties. The FDA has never approved clenbuterol for human use in the U.S.

The cardiac risk profile is distinct from SARMs. Beta-2 agonism at pharmacological doses produces:

• Tachycardia and palpitations, reported in the majority of human case series at doses above 40 mcg/day
• Hypokalemia from transcellular potassium shifts, which can precipitate ventricular arrhythmia
• Cardiac hypertrophy with fibrosis on prolonged exposure, documented in animal models and supported by human autopsy and imaging data

A 2018 case series published in the Journal of Medical Toxicology described 11 patients who presented to emergency departments after clenbuterol use, primarily for weight loss or athletic performance [10]. Heart rates on presentation ranged from 110 to 168 beats per minute. Four patients had ECG changes including QTc prolongation above 500 ms. Two required intravenous beta-blockade. All recovered, but two were admitted to cardiac monitoring units for 24 to 48 hours.

The mechanism of cardiac hypertrophy with prolonged clenbuterol use appears to involve pathological rather than physiological remodeling. Beta-2 stimulation activates protein kinase A pathways that initially resemble exercise-induced hypertrophy but with sustained stimulation produce interstitial fibrosis, reduced ventricular compliance, and impaired diastolic function. A 2012 study in the American Journal of Physiology found that 2 weeks of clenbuterol at 1 mg/kg/day in rodents produced an 18% increase in heart mass alongside a significant reduction in myocardial contractile reserve [11].

Clinicians evaluating patients who use clenbuterol for body composition should obtain a 12-lead ECG, a metabolic panel (specifically potassium and magnesium), and a focused cardiac history. Any resting heart rate above 100 beats per minute or QTc above 450 ms (males) or 470 ms (females) is an indication to stop use immediately.

Warning Signs of SARM Liver Injury

Most patients with SARM-related DILI present with nonspecific symptoms initially. Fatigue and right upper quadrant discomfort precede jaundice by 1 to 3 weeks in the majority of published cases. Dark urine and clay-colored stools indicate cholestasis and suggest more significant biliary involvement.

Symptoms that warrant same-day medical evaluation:

• Jaundice (yellowing of skin or sclera)
• Pruritus (itching) without rash
• Right upper quadrant pain that is constant rather than episodic
• Nausea combined with dark urine
• Confusion or altered mental status (a late sign suggesting hepatic encephalopathy)

A user who is asymptomatic but has been using SARMs for more than 4 weeks should consider a baseline LFT panel. This is not standard guidance from any professional society because no society endorses SARM use, but from a harm-reduction standpoint it is the practical recommendation that allows early detection before jaundice develops.

Who Is at Greatest Risk?

Not every SARM user develops liver injury. Several factors appear to increase individual susceptibility, based on the DILI literature more broadly.

Genetic polymorphisms in cytochrome P450 enzymes (particularly CYP3A4 and CYP1A2) alter the rate at which SARMs are metabolized to reactive intermediates. Slow metabolizers may accumulate higher concentrations of hepatotoxic metabolites. Pre-existing liver disease, including non-alcoholic fatty liver disease, reduces hepatic reserve and lowers the threshold for clinically apparent injury. Concurrent use of other hepatotoxic agents, such as acetaminophen above 2 g/day, alcohol, or anabolic-androgenic steroids, compounds the risk additively or synergistically.

Age and sex may play roles as well. The published SARM case reports skew heavily male (approximately 90%) and young (median age around 28 to 35 years). Whether this reflects true biological susceptibility or simply the demographic that uses these compounds is unclear.

Dose and duration are the most modifiable risk factors a user controls. Every documented severe case involved cycles of 4 weeks or longer, and several involved doses at the high end of the self-reported range (>20 mg/day for ostarine, >10 mg/day for LGD-4033). No dose has been established as safe.

What Safer Alternatives Exist?

For people seeking body composition changes within a medical framework, several FDA-approved and better-characterized options exist.

Testosterone replacement therapy (TRT): In men with confirmed hypogonadism (two morning total testosterone values <300 ng/dL plus symptoms), TRT through injectable testosterone cypionate or enanthate, transdermal gels, or FDA-approved oral testosterone undecanoate (Jatenzo, Tlando, Kyzarod) carries a well-defined safety profile developed over decades of pharmacovigilance. Liver toxicity is not a meaningful risk with non-alkylated testosterone forms. Liver enzyme monitoring is not required by the FDA for injectable or transdermal testosterone [12].

GLP-1 receptor agonists for fat loss: Semaglutide 2.4 mg weekly (Wegovy) produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo in STEP-1 (N=1,961) [13]. This is a regulatory-approved mechanism with a defined adverse-effect profile that does not include liver toxicity.

Resistance training and protein intake optimization: Tedious to mention but not trivial. A meta-analysis of 49 studies (N=1,327) published in the British Journal of Sports Medicine found that protein supplementation above 1.62 g/kg/day produced no additional lean mass gain in trained individuals, suggesting that most users seeking SARM-like results have not yet optimized the free, legal, and safe variables available to them [14].

The appeal of SARMs is understandable. The biology of selective androgen receptor modulation is genuinely interesting, and the original hypothesis was reasonable. The current reality is that no human safety data exist at the doses used recreationally, no regulatory body has cleared any SARM for human use, and the case report literature documents liver injury serious enough to require hospitalization in otherwise healthy young adults.